Equities

BrightPath Biotherapeutics Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4594:TYO

BrightPath Biotherapeutics Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)67.00
  • Today's Change-5.00 / -6.94%
  • Shares traded9.63m
  • 1 Year change+45.65%
  • Beta1.5970
Data delayed at least 15 minutes, as of Feb 20 2026 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.

  • Revenue in JPY (TTM)1.11m
  • Net income in JPY-1.08bn
  • Incorporated2003
  • Employees24.00
  • Location
    BrightPath Biotherapeutics Co Ltd7F, Kojimachi Central Bldg2-2-4, Koji-machiCHIYODA-KU 102-0083JapanJPN
  • Phone+81 444403939
  • Fax+81 942386564
  • Websitehttps://www.brightpathbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Modalis Therapeutics Corp0.00-2.15bn4.99bn14.00--1.77-----28.13-28.130.0032.230.00-------64.69-47.62-67.23-49.48-------22,365.60-------------63.34---68.51--
D.Western Therapeutics Institute Inc387.62m-632.09m5.43bn21.00--3.78--14.00-13.31-13.318.0926.460.20190.41153.53---32.93-28.15-36.09-30.6889.9792.09-163.07-155.999.48--0.2966---17.801.7451.01---11.74--
Carna Biosciences, Inc.579.06m-2.17bn6.12bn63.00--19.74--10.58-113.62-113.6230.3016.160.28941.246.17---108.53-37.21-120.28-41.9867.0386.49-375.00-118.286.08-75.550.6979---8.99-12.570.3262---33.02--
TMS Co Ltd0.00-693.96m6.46bn18.00--2.33-----15.47-15.470.0060.920.00-------24.01---24.96----------30.41------------------
Cyfuse Biomedical KK-100.00bn-100.00bn6.53bn21.00--2.28----------286.90-----------13.87---16.49--68.61---178.864.44--0.3224--324.2710.9412.43--182.58--
Noile-Immune Biotech Inc5.00m-793.54m6.76bn25.00--1.72--1,351.02-18.33-18.330.115590.800.0011--0.1129---18.01-17.82-18.31-18.34-----15,870.72-385.4153.51-------34.10-44.7717.72------
Tsubota Laboratory Inc710.56m-398.77m6.78bn17.00--6.14--9.55-15.53-15.5327.5542.860.35940.452250.4641,797,700.00-20.170.1041-29.560.151781.6571.43-56.120.22162.60--0.06340.00101.4925.17132.08132.7026.42--
PRISM BioLab Co Ltd684.61m-927.75m7.53bn35.00--3.09--11.01-25.27-25.2718.6466.060.1886--8.7919,560,140.00-25.55---32.06--38.47---135.52-----77.050.00--121.62--20.56------
Linical Co Ltd9.32bn-1.77bn7.74bn598.00--1.25--0.8309-78.51-78.51412.61251.020.5937--3.6215,584,280.00-11.302.59-20.504.1917.4829.24-19.033.74---192.930.293377.26-15.20-0.9283-259.37---42.014.24
OncoTherapy Science, Inc.784.25m-881.65m7.91bn47.00--3.70--10.09-2.93-2.932.605.680.42248.388.7216,686,090.00-47.48-63.66-56.22-77.433.63-0.3852-112.42-184.758.13-832.790.0043--22.9318.8636.71---70.80--
Chiome Bioscience Inc593.29m-982.78m7.99bn47.00--7.01--13.46-14.48-14.488.7416.390.28284.979.64---46.84-52.22-59.06-64.4159.9357.59-165.65-174.883.99-1,177.610.1891---24.024.293.72------
Chordia Therapeutics Inc0.00-1.46bn8.53bn20.00--3.58-----21.23-21.230.0032.670.00----0.00-46.77---49.97-------------222.950.00------2.26------
BrightPath Biotherapeutics Co Ltd1.11m-1.08bn8.83bn24.00--4.89--7,953.53-11.59-11.590.011713.700.0007----46,250.00-63.35-59.65-74.36-63.7897.6673.74-96,860.36-28,727.67---1,103.910.00--1,473.61-36.871.45---58.41--
Medinet Co Ltd787.09m-1.36bn9.06bn107.00--2.63--11.52-5.12-5.122.9712.950.170111.083.007,355,991.00-29.29-22.42-31.04-23.6413.5817.68-172.25-173.5911.33--0.00--5.440.6867-6.67--10.06--
Kidswell Bio Corp7.06bn23.83m12.90bn37.00227.136.70527.151.831.141.14150.1138.831.306.3823.34190,934,200.000.4375-16.750.678-27.0627.4547.460.3374-28.292.76--0.5768--109.0336.3798.51--27.20--
Data as of Feb 20 2026. Currency figures normalised to BrightPath Biotherapeutics Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

0.20%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 05 Feb 2026224.90k0.17%
SPARX Asset Management Co., Ltd.as of 11 Mar 202433.50k0.03%
Data from 31 Dec 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.